OrbiMed’s Invitae Corporation NVTA Stock Holding History

OrbiMed’s Portfolio NVTA Stock Details NVTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-222,017	Closed	-$5.2M	–	140
2019 Q1	$5.2M	Sell	222,017 -602,532	-73%	-$10.6M	0.08%	107
2018 Q4	$9.12M	Sell	824,549 -450,000	-35%	-$5.83M	0.17%	89
2018 Q3	$21.3M	Sell	1,274,549 -243,648	-16%	-$2.77M	0.26%	84
2018 Q2	$11.2M	Hold	1,518,197	–	–	0.13%	109
2018 Q1	$7.12M	Hold	1,518,197	–	–	0.09%	112
2017 Q4	$13.8M	Hold	1,518,197	–	–	0.17%	92
2017 Q3	$14.2M	Buy	1,518,197 +1,061,531	+232%	+$10.1M	0.14%	97
2017 Q2	$4.37M	Hold	456,666	–	–	0.05%	118
2017 Q1	$5.05M	Hold	456,666	–	–	0.06%	116
2016 Q4	$3.63M	Hold	456,666	–	–	0.05%	115
2016 Q3	$4M	Hold	456,666	–	–	0.05%	120
2016 Q2	$3.38M	Hold	456,666	–	–	0.04%	116
2016 Q1	$4.67M	Hold	456,666	–	–	0.05%	117
2015 Q4	$3.75M	Hold	456,666	–	–	0.03%	113
2015 Q3	$3.3M	Hold	456,666	–	–	0.03%	120
2015 Q2	$6.79M	Hold	456,666	–	–	0.06%	116
2015 Q1	$7.65M	Buy	+456,666	New	+$8.46M	0.07%	111

Other funds holding NVTA

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

OrbiMed's NVTA Position: Q2 2019 in Review

OrbiMed sold out of Invitae Corporation (NVTA) in Q2 2019, closing a stake of 222,017 shares — an estimated $5.2M sold.

OrbiMed first reported a position in NVTA in Q1 2015 and held it in 17 quarters. The position peaked at $21.3M in Q3 2018. 162 funds tracked by Wall St. Rank hold NVTA as of Q2 2019.

OrbiMed reported no remaining Invitae Corporation position as of Q2 2019 after selling out during the quarter.
OrbiMed sold 222,017 Invitae Corporation shares in Q2 2019, an estimated $5.2M.
OrbiMed first reported a position in Invitae Corporation in Q1 2015 and held it in 17 quarters.
OrbiMed's Invitae Corporation position peaked at $21.3M in Q3 2018.
162 funds tracked by Wall St. Rank held Invitae Corporation as of Q2 2019.

Based on OrbiMed's 13F filing for Q2 2019, filed 14 Aug 2019.